We have a clear strategy to become a leading biotech company focused on the discovery and development of targeted medicines for current unmet medical needs for serious diseases for which there are no existing treatments.  

Graviton has a diverse pipeline and multiple value inflection points that demonstrate our advanced clinical development and immense commercial opportunity. 

Our corporate strategy to achieve this is a two-pronged approach: 

1.     Select highly targeted areas that address unmet medical needs, that we believe our science and drug discovery capabilities will treat; and
2.     Develop and deliver drugs with a viable path to clinical success.